SEC Filing Summary

This filing details transactions made by Gary Charles Robb, Chief Business Officer of CORCEPT THERAPEUTICS INC. On May 27, 2026, Robb disposed of 600 shares of Common Stock with a transaction price of $0.00, resulting in 25,081 shares remaining post-transaction. The filing also reports indirect ownership of shares held in custodial accounts for a child and within the Gary Charles Robb TTE Robb Revocable Trust. Footnote F1 provides details on 251 shares underlying unvested restricted stock awards granted on September 2, 2025, with similar grants on December 1, 2025, March 2, 2026, and June 1, 2026, all subject to a one-year vesting period. The shares in custodial accounts are held for the benefit of Robb's child, with Robb acting as custodian. The shares in the revocable trust are held with Robb as trustee. The filing was signed on July 8, 2026, with Joseph Douglas Lyon acting as attorney-in-fact for Robb.